17/09/2026
Most life sciences companies still treat translation as an afterthought.
They finalise the protocol, design the materials, and only then ask:
“Who will translate this for our target markets?“
Here is the problem.
Every delay, every amendment, every back and forth with an ethics committee because of wording, has a direct cost on your time to market.
What most teams think localisation is
→ Turning the English text into another language at the end.
What localisation really is
→ Designing patient and HCP communication so it works naturally in each language from day one.
In clinical trials and pharma communications, that means
→ Involving linguists who understand regulatory expectations when you draft patient materials.
→ Stress testing terminology with local affiliates instead of assuming literal equivalents.
→ Aligning tone and reading level with health literacy norms in each country.
The business impact is very simple.
Trials recruit faster when consent forms are clear and culturally appropriate.
Regulators raise fewer questions when risk wording is unambiguous.
Sales teams launch with materials that feel native, not translated.
If you are a CEO, CMO or Export Director in life sciences, you do not need to become a linguist.
You do need to start treating language as part of your product strategy, not the last line in your Gantt chart.
